Thursday, November 12, 2026

defense

3 articles

Pentagon's 2027 Chinese Rare Earth Ban Reshapes Global Defense Supply Chains

Pentagon's 2027 Chinese Rare Earth Ban Reshapes Global Defense Supply Chains

The U.S. Department of Defense has mandated defense contractors eliminate Chinese rare earth elements from supply chains by 2027. The move challenges China's 70% control of global rare earth processing and forces creation of parallel supply networks. Domestic producers race to build capacity as the deadline threatens billions in defense contracts.

LM Salvado•
ZenaTech Develops Low-Cost Interceptor Drone for Counter-Drone Defense

ZenaTech Develops Low-Cost Interceptor Drone for Counter-Drone Defense

ZenaTech announced development of a single-use autonomous interceptor drone designed for counter-drone operations in U.S. defense, Middle East and Ukraine applications. The prototype development by the company's ZenaDrone subsidiary targets hostile drone threats.

LM Salvado•
U.S. Defense Contractors Deploy Layered AI Systems as Military Automation Contracts Accelerate

U.S. Defense Contractors Deploy Layered AI Systems as Military Automation Contracts Accelerate

VisionWave Systems secured a seven-figure defense contract in January 2025 for hierarchical AI in air and ground operations, while the U.S. Army established a framework with Appian for enterprise automation. The moves reflect Pentagon efforts to match China's military AI investments, with custom Intel-NVIDIA processors addressing security requirements commercial chips cannot meet.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com